Drug Search Results
More Filters [+]

Nelivaptan

Alternative Names: nelivaptan, ssr149415
Latest Update: 2023-08-11
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: V3 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nelivaptan

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OLIVE

P2

Active, not recruiting

Depressive Disorder, Major

2024-08-14

Recent News Events